that of patients remaining at normal weight throughout treatment.
Conversely, for patients who began treatment obese or underweight
and subsequently attained normal/overweight status, this risk was
reduced to be equivalent to having normal weight throughout. These
findings may provide an explanation for the inconsistency among
earlier reports, which did not account for weight changes during
therapy. Moreover, obese or underweight patients were found to be at
higher risk for distinct toxicity profiles, an important independent
consideration in efforts to reduce morbidity resulting from effective
but toxic treatment regimens.